Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Priya Nigam

Why This Analyst Feels It's Time To Short Embecta

Despite being a market leader in insulin pen needles and syringes, Embecta Corp (NASDAQ:EMBC) may face challenges ahead, since the markets are already mature and the company has not diversified, according to BofA Securities.

The Embecta Analyst: Travis Steed initiated coverage of Embecta with an Underperform rating and a price target of $25.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.